Cynosure To Distribute Nitrous Oxide and Oxygen System in Aesthetics Market

Cynosure enters into agreement with Parker Hannifin

Hologic’s Cynosure division has entered into an agreement with Porter Instrument, a business unit of Parker Hannifin Corporation, for distribution rights in the United States and Canada to Porter’s Nitronox nitrous oxide and oxygen system. Nitronox is a self-administered nitrous oxide and oxygen delivery system providing a fast-acting inhaled analgesic that helps patients manage potential discomfort and anxiety while remaining alert and conscious during their aesthetic procedures.

Hologic To Acquire Cynosure

Hologic—a developer, manufacturer and supplier of diagnostic products, medical imaging systems and surgical products—and laser manufacturer Cynosure have signed a definitive agreement for Hologic to acquire all outstanding Cynosure shares for $66.00 per share in cash, for a total cost of approximately $1.65 billion. The boards of directors of both companies have approved the transaction unanimously.

PicoSure Receives FDA Marketing Clearance for Tattoos and Pigmented Lesions

PicoSure Approved for Tattoo Removal

Laser manufacturer Cynosure has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its PicoSure picosecond laser for the removal of the full spectrum of tattoo inks as well as pigmented lesions.

The device’s new 1064nm wavelength aids in removal of black and other dark tattoo inks and complements the system’s existing 532nm and 755nm wavelengths. It will be offered as an upgrade to existing PicoSure customers, and initial shipments of the new 1064nm laser delivery system are expected to begin in the second half of 2016.

Laser Lipolysis

Main Image: 
Laser Lipolysis

The SculpSure platform from Cynosure has received 510(k) clearance for noninvasive fat reduction. SculpSure is the first hyperthermic laser treatment approved for noninvasive lipolysis of the flanks and abdomen. The hands-free device features a 1060nm laser and a flexible applicator system to disrupt subcutaneous fat cells in approximately 25 minutes with no downtime. Contact: 888.523.2233,

No, don't share this with BeautyEtc

FDA Approves PicoSure 532nm Delivery System

FDA Approves PicoSure 532nm Delivery System

Cynosure has received U.S. Food and Drug Administration (FDA) clearance for its new 532nm laser delivery system for the PicoSure. The new wavelength is indicted for tattoo removal (all ink colors).

“The new 532nm Laser Delivery System further builds on the clinical and commercial success of the 755nm PicoSure for the removal of tattoos and benign pigmented lesions as well as the treatment of acne scars and wrinkles,” said Michael Davin, chairman and CEO of Cynosure. “We are pleased to offer this system as an upgrade to our current PicoSure customer base.”

Cynosure Promotes Aronson to VP of North American Sales

Chris Aronson is the new vice president of North American sales for device manufacturer Cynosure. Aronson previously served as the company’s director of sales (eastern area). He will be responsible for managing the company’s North American direct distribution channel and expanding customer relationships throughout the region. He will report to Doug Delaney, executive vice president of worldwide sales. Prior to joining Cynosure in 2003, Aronson was regional sales director for Stryker Endoscopy.

Cynosure Acquires Ellman International

Cynosure has acquired Ellman International’s assets for approximately $13.2 million cash. Ellman makes the radiofrequency-based Pelleve and Pellefirm skin-tightening systems as well as the Sandstone line of medical aesthetic lasers.
“This transaction complements our brand portfolio, expands our market opportunities and enhances our recurring revenue stream,” said Michael Davin, chairman and CEO of Cynosure. “Ellman's RF product line broadens our technology platform, while its aesthetic lasers allow us to offer a value solution at a different price point than our current offerings.”